Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Therapeutic Advances in Urology
|
April 2, 2016
Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials
Peter Iversen, Jan-Erik Damber, Anders Malmberg, et al.
The Journal of Urology
|
September 20, 2008
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America
Marc Gittelman, Peter J Pommerville, Bo-Eric Persson, et al.
The Journal of Urology
|
October 19, 2010
Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer
Matthew R Smith, Laurence Klotz, Bo-Eric Persson, et al.
European Urology
|
January 21, 2014
Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists
Laurence Klotz, Kurt Miller, E David Crawford, et al.
European Urology
|
June 10, 2008
Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer
Hendrik Van Poppel, Bertrand Tombal, Jean J de la Rosette, et al.
Urologia Internationalis
|
December 22, 2012
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)
John Anderson, Ghandi Al-Ali, Manfred Wirth, et al.
BJU International
|
November 17, 2009
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
Fritz H Schröder, Bertrand Tombal, Kurt Miller, et al.
BJU International
|
November 28, 2008
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
Laurence Klotz, Laurent Boccon-Gibod, Neal D Shore, et al.
European Urology
|
December 8, 2009
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics
Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, et al.
Urology
|
July 4, 2012
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients
Jan-Erik Damber, Teuvo L J Tammela, Peter Iversen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Therapeutic Advances in Urology
|
April 2, 2016
Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials
Peter Iversen, Jan-Erik Damber, Anders Malmberg, et al.
The Journal of Urology
|
September 20, 2008
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America
Marc Gittelman, Peter J Pommerville, Bo-Eric Persson, et al.
The Journal of Urology
|
October 19, 2010
Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer
Matthew R Smith, Laurence Klotz, Bo-Eric Persson, et al.
European Urology
|
January 21, 2014
Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists
Laurence Klotz, Kurt Miller, E David Crawford, et al.
European Urology
|
June 10, 2008
Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer
Hendrik Van Poppel, Bertrand Tombal, Jean J de la Rosette, et al.
Urologia Internationalis
|
December 22, 2012
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)
John Anderson, Ghandi Al-Ali, Manfred Wirth, et al.
BJU International
|
November 17, 2009
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
Fritz H Schröder, Bertrand Tombal, Kurt Miller, et al.
BJU International
|
November 28, 2008
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
Laurence Klotz, Laurent Boccon-Gibod, Neal D Shore, et al.
European Urology
|
December 8, 2009
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics
Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, et al.
Urology
|
July 4, 2012
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients
Jan-Erik Damber, Teuvo L J Tammela, Peter Iversen, et al.
Page
of 3